Clinical Trial

COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of this study is to assess the efficacy of the COMBO Endoscopy Oropharyngeal Airway in reducing the incidence of hypoxia in patients undergoing ERCP under sedation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-02.
Status change: Not Yet Recruiting → Recruiting 2025-06-23
Trial Details
NCT Number NCT07012772
Lead Sponsor Zhejiang University
Conditions Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis, Cholelithiasis
Enrollment 50 participants
Start Date 2025-06-12
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-24